Business
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ? $150 Million and Provides Q1 2026 Outlook
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSX...
About this update from Hydreight Technologies Inc
[{"type":"text","content":"Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook\nVANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and on-demand healthcare services across the United States, today issued revenue guidance for the fiscal year ending December 31, 2026, and provided an outlook for the first quarter of fiscal 2026. Fiscal 2026 Revenue Guidance Based on current internal planning assumptions, the Company expects fiscal 2026 revenue of approximately $150 million, representing a conservative baseline outlook reflecting currently contracted demand and visible partner activity.¹ This guidance is intended to represent a baseline or “floor-case” scenario and assumes continued execution across the Company’s existing pharmacy operations and digital health platform. The guidance excludes any potential incremental contributions from acquisitions, new geographic market entries, or commercial arrangements that are not currently operational as of the date of this release. Q1 2026 Revenue Outlook The Company expects revenue to increase throughout fiscal 2026 as several major partnerships, clients, and pharmacy product lines that were planned and implemented in late 2025 and early 2026 go live. Based on current visibility and contracted activity, the Company expects revenue for the first quarter of fiscal 2026 to be in the range of approximately $25 million to $28 million. Cost Structure, Margin and Profitability Context The Company’s fiscal 2026 guidance assumes no material increase in fixed operating costs relative to late-2025 levels. Hydreight has already established its national regulatory, pharmacy, and technology infrastructure, and management expects incremental revenue growth to be supported largely by this existing cost base. Based on current internal planning assumptions, and assuming fiscal 2026 revenue of approximately $150 million, management expects the Company to generate an Adjusted EBITDA margin of approximately 15–17%.² This reflects the anticipated benefit of scaling transaction volumes across a largely fixed operating cost structure. While the Co...